A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 29 Mar 2018
At a glance
- Drugs Roxadustat (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ROCKIES
- Sponsors AstraZeneca
- 23 Mar 2018 Planned End Date changed from 2 Apr 2018 to 25 Sep 2018.
- 23 Mar 2018 Planned primary completion date changed from 2 Apr 2018 to 25 Sep 2018.
- 13 Dec 2017 Planned number of patients changed from 2100 to 2070.